MedTrace Logo

A Clinical Evaluation of the LensGen Intraocular Lens

NCT05364658 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-03-09

No results posted yet for this study

Summary

A multi-center, open-label, non-comparative clinical trial to assess the safety and efficacy of the LensGen IOL (Juvene IOL) for the treatment of aphakia and presbyopia after removal of the natural crystalline lens due to cataract.

Conditions

Interventions

DEVICE

Juvene IOL

Indicated for Implantation in the human eye after removal of a cataractous crystalline lens

Sponsors & Collaborators

  • LensGen, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick R Casey, O.D. · LensGen, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-18
Primary Completion
2019-11-30
Completion
2020-01-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364658 on ClinicalTrials.gov